Antitumor activity of copanlisib in lymphoma cell lines other than DLBCL
| . | No. of cell lines . | Median IC50, nM . | 95% CI, nM . |
|---|---|---|---|
| All cell lines | 26 | 75 | 21-160 |
| B-cell lymphomas | 17 | 22 | 15-99 |
| MCL | 10* | 21.5 | 3-103 |
| MZL | 6† | 36 | 6-175 |
| CLL | 1‡ | 23 | n.d. |
| T-cell lymphomas | 9 | 285 | 137-926 |
| CTCL | 3§ | 304 | 131-970 |
| ALCL, ALK+ | 4|| | 215 | 50-285 |
| ALCL, ALK− | 1¶ | 399 | n.d. |
| PTCL-NOS | 1# | 1663 | n.d. |
| . | No. of cell lines . | Median IC50, nM . | 95% CI, nM . |
|---|---|---|---|
| All cell lines | 26 | 75 | 21-160 |
| B-cell lymphomas | 17 | 22 | 15-99 |
| MCL | 10* | 21.5 | 3-103 |
| MZL | 6† | 36 | 6-175 |
| CLL | 1‡ | 23 | n.d. |
| T-cell lymphomas | 9 | 285 | 137-926 |
| CTCL | 3§ | 304 | 131-970 |
| ALCL, ALK+ | 4|| | 215 | 50-285 |
| ALCL, ALK− | 1¶ | 399 | n.d. |
| PTCL-NOS | 1# | 1663 | n.d. |
n.d., not determined; PTCL-NOS, PTCL–not otherwise specified.
GRANTA-519, JEKO1, JVM-2, MAVER-1, MINO, REC-1, SP-49, SP-53, UPN-1, Z-138. †KARPAS1718, VL51, SSK41, ESKO-L, HAIR-M, HC-1. ‡MEC-1. §H9, HH, HUT78. ||Ki-JK, KARPAS-299, L-82, SU-DHL-1. ¶MAC-1. #FE-PD.